Patents by Inventor Bruce A. Sherf

Bruce A. Sherf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7842792
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration.
    Type: Grant
    Filed: December 30, 2002
    Date of Patent: November 30, 2010
    Assignee: ABT Holding Company
    Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
  • Publication number: 20100010196
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by nontargeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell.
    Type: Application
    Filed: June 26, 2009
    Publication date: January 14, 2010
    Applicant: ABT Holding Company
    Inventors: John Joseph Harrington, Bruce Sherf, Stephen Rundlelt
  • Patent number: 7569220
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: August 4, 2009
    Assignee: ABT Holding Company
    Inventors: John Joseph Harrington, Bruce A. Sherf, Stephen E. Rundlett
  • Patent number: 7420044
    Abstract: The present invention relates to the identification of novel nucleic acid molecules and the proteins encoded by these nucleic acid molecules, as well as their production for use as therapeutics, diagnostics and for research purposes.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: September 2, 2008
    Assignee: ABT Holding Company
    Inventors: John J. Harrington, P. David Jackson, Bruce A. Sherf, Scott Cain, Stephen E. Rundlett, Rakesh Ramachandran
  • Patent number: 7316923
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by non-targeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: January 8, 2008
    Assignee: Athersys, Inc.
    Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
  • Publication number: 20070178585
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.
    Type: Application
    Filed: August 5, 2003
    Publication date: August 2, 2007
    Applicant: ATHERSYS, INC.
    Inventors: John Harrington, Bruce Sherf, Stephen Rundlett
  • Publication number: 20070122391
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.
    Type: Application
    Filed: September 6, 2005
    Publication date: May 31, 2007
    Applicant: ATHERSYS, INC.
    Inventors: John Harrington, Bruce Sherf, Stephen Rundlett
  • Publication number: 20070111280
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.
    Type: Application
    Filed: September 2, 2005
    Publication date: May 17, 2007
    Inventors: John Harrington, Bruce Sherf, Stephen Rundlett
  • Publication number: 20060105318
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. The invention is specifically directed to methods of drug discovery using the activated gene products for compound testing.
    Type: Application
    Filed: January 18, 2000
    Publication date: May 18, 2006
    Inventors: John Harrington, Bruce Sherf, Stephen Rundlett
  • Publication number: 20040162416
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by non-targeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell.
    Type: Application
    Filed: January 17, 2001
    Publication date: August 19, 2004
    Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
  • Patent number: 6740503
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the, sequence, structure, function, or expression profile of the genes.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: May 25, 2004
    Assignee: Athersys, Inc.
    Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
  • Patent number: 6670185
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. The invention also provides methods for isolation of nucleic acid molecules (particularly cDNA molecules) encoding a variety of proteins.
    Type: Grant
    Filed: January 7, 2000
    Date of Patent: December 30, 2003
    Assignee: Athersys, Inc.
    Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
  • Publication number: 20030180267
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration.
    Type: Application
    Filed: December 30, 2002
    Publication date: September 25, 2003
    Applicant: Athersys, Inc.
    Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
  • Patent number: 6623958
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by non-targeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: September 23, 2003
    Assignee: Athersys, Inc.
    Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
  • Patent number: 6602686
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. The invention also provides methods for isolation of nucleic acid molecules (particularly cDNA molecules) encoding a variety of proteins.
    Type: Grant
    Filed: December 7, 1999
    Date of Patent: August 5, 2003
    Assignee: Athersys, Inc.
    Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
  • Patent number: 6541221
    Abstract: Expression of an endogenous gene is activated or increased following integration into a cell, by non-homologous or illegitimate recombination, of (1) an enhancer sequence that activates expression of the gene and (2) a sequence that encodes an amplifiable marker. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. The invention also provides cells containing the enhancer and amplifiable marker sequence and expressing increased amounts of a desired gene. The invention also provides methods for the isolation of nucleic acid molecules (particularly cDNA molecules) encoding a variety of proteins, including transmembrane proteins, and for the isolation of cells expressing such proteins.
    Type: Grant
    Filed: January 11, 2000
    Date of Patent: April 1, 2003
    Assignee: Athersys, Inc.
    Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
  • Patent number: 6524824
    Abstract: Expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. The invention also provides methods for the isolation of nucleic acid molecules (particularly cDNA molecules) encoding a variety of proteins, including transmembrane proteins, and for the isolation of cells expressing such transmembrane proteins which may be heterologous transmembrane proteins. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.
    Type: Grant
    Filed: January 12, 2000
    Date of Patent: February 25, 2003
    Assignee: Athersys, Inc.
    Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
  • Patent number: 6524818
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by non-targeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: February 25, 2003
    Assignee: Athersys, Inc.
    Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
  • Patent number: 6361972
    Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by non-targeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell.
    Type: Grant
    Filed: January 10, 2000
    Date of Patent: March 26, 2002
    Assignee: Athersys, Inc.
    Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
  • Patent number: 5798263
    Abstract: The presently disclosed invention is drawn to an automatic luminometer apparatus capable of measuring two distinct luminescent reactions from within a single, non-compartmentalized sample container. The present apparatus may be dimensioned, configured, and programmed to automatically perform dual-reporter luminescent assays using multi-well sample plates, such as 96-well microtiter plates.
    Type: Grant
    Filed: September 5, 1996
    Date of Patent: August 25, 1998
    Assignee: Promega Corporation
    Inventors: Keith V. Wood, Bruce A. Sherf